News

Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks

  • Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.
    03/26/2024

10 Best-Performing Penny Stocks in the Health Care Sector

  • The healthcare sector has more high return generating companies than many other sectors.
    04/03/2023
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Dianthus Therapeutics, Inc. (DNTH) can hold. Click on Rating Page for detail.

The price of Dianthus Therapeutics, Inc. (DNTH) is 25.535 and it was updated on 2024-04-12 13:00:37.

Currently Dianthus Therapeutics, Inc. (DNTH) is in undervalued.

News
    
News

Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks

  • Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).
    Thu, Mar. 30, 2023

MGTA Stock: 51.66% Surge Explained

  • The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why.
    Sun, Feb. 05, 2023

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

  • Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
    Wed, Dec. 21, 2022

Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%

  • The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why.
    Tue, Dec. 20, 2022

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

  • CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
    Mon, Dec. 12, 2022
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

  • The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
  • 05/16/2022

Magenta Therapeutics Trims R&D, Cuts Workforce

  • Magenta Therapeutics Inc (NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research.
  • 04/14/2022

Big Pharma Is Going Holiday Shopping. Who's Next?

  • After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
  • 11/10/2021

Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

  • Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high of 22 out of 37 weeks this year in negative conditions above the 40 MG level.
  • 09/19/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S.
  • 08/03/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • New York, New York--(Newsfile Corp. - August 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Magenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
  • 08/01/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, July 21, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S.
  • 07/21/2021

After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

  • Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
  • 07/14/2021

Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma, which were accepted for presentation at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021. Magenta also provide
  • 05/12/2021

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presentations across its stem cell mobilization and targeted conditioning programs at the European Society for Blood and Marrow Transplantation (EBMT) 2021 annual meeting, held virtually March 14-17, 2021. “The EBMT Annual Meeting is one of the most imp
  • 03/15/2021

Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Thursday, March 18th, 2021, at 10:00 a.m. ET. A live webcast of the presentation can be accessed on the Magenta Therapeutics website at https://investor.m
  • 03/09/2021

Magenta Is Ready to Paint Your Portfolio Green

  • This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.
  • 02/27/2021

Gain Therapeutics Aims For $40 Million IPO

  • Gain Therapeutics has filed to raise $40 million in a U.S. IPO.
  • 02/25/2021

Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (TCT) 2021 Annual Meeting

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021. “Magenta continues to generate encouragin
  • 02/08/2021

Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced final clinical results from its earlier completed Phase 1 clinical trial as well as development updates for its MGTA-145 stem cell mobilization therapy, including commencement of enrollment in a Phase 2 clinical trial in multiple myeloma, and its plans for a Phase 2 clinical
  • 12/07/2020

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patien
  • 12/04/2020

34,200 Shares in Magenta Therapeutics Inc (NASDAQ:MGTA) Acquired by Tudor Investment Corp Et Al

  • Tudor Investment Corp Et Al bought a new position in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 34,200 shares of the company’s stock, valued at approximately $257,000. Tudor Investment Corp Et Al owned about 0.07% of Magenta Therapeutics […]
  • 09/18/2020

The Low Down On Magenta Therapeutics

  • Busted IPO Magenta Therapeutics, Inc. executed a late-June secondary at $8, shortly after announcing it was abandoning a Phase 2 trial due to enrollment challenges.
  • 08/31/2020

3 Healthcare Stocks Under $10 With Massive Upside Ahead

  • Which stocks are leading the pack out on Wall Street? Biotechs. Understandably, investors have taken a more cautious approach when navigating the confused financial environment, but focus is locking in on the healthcare sector as it has been able to withstand the COVID-19-induced pressure on the market. The space’s resilience combined with a limited impact on Q1 fundamentals and the elimination of macro headwinds regarding drug legislation, has caused sentiment surrounding 2H20 performance to swing strongly positive.While there certainly are exciting opportunities at play, biotech stocks aren’t for the faint of heart. Seasoned market watchers know that they are notoriously volatile, prone to huge movements on account of a single update. This makes them riskier investments, but it also enables them to deliver massive returns. As a result, it can be hard to gauge which biotech names are primed for explosive growth. Not to worry, there are strategies that can help make this process a little easier like taking a cue from the analysts.With this in mind, we turned to investment firm Wedbush to get some investing inspiration. Using TipRanks database, we got a closer look at three of the firm's Buy-rated picks, which happen to trade for less than $10 per share. The cherry on top? The firm's analysts believe that each of the tickers could see their share prices take flight over the next months. Five Prime Therapeutics (FPRX)Developing protein therapeutics designed to address the needs of patients, Five Prime Therapeutics hopes to be able to provide innovative new treatment options. Ahead of potential near-term inflection points, shares are changing hands for $4.65 apiece, reflecting an attractive entry point, according to Wedbush.Pointing to the upcoming clinical data readouts for FPT155 and bemarituzumab, firm analyst Robert Driscoll believes these events are “important value drivers for the company.” Phase 1 monotherapy data for FPT155 in advanced solid tumors, which will include a first look at efficacy, could come by YE:20. As for bemarituzumab, data from the Phase 2 FIGHT study evaluating the therapy in combination with mFOLFOX6 in frontline Gastric/ GEJ cancer is slated to readout by YE:20 or early 2021. Management is expecting the FIGHT study to yield enough PFS and OS events to meet this timeline.“Given these upcoming readouts, we see a favorable risk/reward profile for shares, particularly given management’s recent substantial strategic clinical development adjustments and corporate restructuring,” Driscoll commented.Looking more closely at FPT155, the Wedbush analyst noted, “We see a lot of value in FPT155’s dual mechanism of action which includes CTLA-4 antagonism and CD28 agonism. We are excited about this mechanism for two reasons – first, CTLA-4 is a clinically validated target that has demonstrated monotherapy and clear combination activity with anti-PD-(L)1s, and second, it has been shown preclinically that CD28 co-stimulation contributes critically to the efficacy of anti-PD1 therapy.”To this end, Driscoll rates FPRX an Outperform (i.e. Buy) along with a $9 price target. Should his thesis play out, a potential upside of 94% could be in the cards. (To watch Driscoll’s track record, click here)   FPRX has kept a relatively low profile, as only one other analyst has thrown an opinion into the mix in the past 3 months. The additional Buy rating means that the stock has a Moderate Buy consensus rating. At $9, the average price target is identical to Driscoll’s. (See FPRX stock analysis on TipRanks)Aravive Inc. (ARAV)Focusing on the targeting signaling pathways that drive the activation, migration and invasion of abnormal cells into healthy tissues, Aravive develops treatments designed to stop life-threatening diseases like cancer and fibrosis in their tracks. Based on its recent clinical results and $5.83 share price, the stock looks “undervalued” to Wedbush.Writing for the firm, 5-star analyst David Nierengarten tells clients that the recent results for AVB-500 in ovarian cancer are encouraging. In the Phase 1b/2 study, the candidate in combination with paclitaxel (PAC) produced overall response rates of 35%, with 3 out of 5 responses in patients dosed in the 15 mg/kg cohort. Additionally, progression free survival (PFS) in patients dosed with the AVB-500 plus paclitaxel combination was 7.4 months.  It should be noted that prior Avastin (bevacizumab) treatment in AVB-500 and PAC patients could lead to worse outcomes (6/10 ORR without prior bevacizumab vs. 2/13 ORR with prior bevacizumab). “Given these Avastin outcomes, it would be interesting to determine if AVB-500 has additional activity in combination, before the patients are Avastin-experienced. We expect the company to explore these and other combinations to move AVB-500 into earlier lines of therapy,” Nierengarten commented. Given other positive trends demonstrating improvements at higher doses and in patients with high sAXL/GAS6 ratios, Nierengarten argues “there is additional evidence that AVB-500 combination therapy could be efficacious in ovarian cancer patients.” He also points out that ARAV wants to design an adaptive study using biomarkers to support eventual approval.With the significant unmet need in the space, Nierengarten believes it's very likely that the trial will ultimately come to fruition. He added, “With an adaptive design, we could see an interim look at the pivotal study data in 2021.” If that wasn’t enough, Nierengarten highlights the fact that “ARAV is planning to begin its Phase 1b/2 study in clear cell renal carcinoma (ccRCC) in 2H20 and potentially look at combinations in earlier lines of ovarian cancer in 2021.”All of this prompted Nierengarten to state, “At just under $4 per share in cash, and ~$35 million enterprise value, with a soon-to-be registration-enabling study in ovarian cancer patients, we view the risk/reward as favorable.”In line with his optimistic take, Nierengarten rates ARAV an Outperform (i.e. Buy), along with a $24 price target. This figure implies upside potential of a massive 320%. (To watch Nierengarten’s track record, click here)Overall, based on all the above factors, Wall Street analysts are thoroughly impressed with ARAV. It boasts 100% Street support, or 4 Buy ratings in the last three months, making the consensus a Strong Buy. If this wasn’t enough, the $27.75 average price target implies that shares could surge 391% in the next twelve months.(See Aravive stock analysts on TipRanks)Magenta Therapeutics Inc. (MGTA)Through its research efforts, Magenta Therapeutics wants to create a world in which patients’ immune systems can be reset via stem cell transplant to cure autoimmune diseases, blood cancers and genetic diseases. With more clarity on its clinical programs set to come in the second half of the year, its $7.28 share price presents investors with an opportunity to get in on the action, if you ask Wedbush.Analyst David Nierengarten, who also covers ARAV, is looking forward to data from the first subjects in MGTA-145's Phase 2 stem cell mobilization studies in H2:20, with the results expected to be readout shortly after enrollment wraps up. On top of this, the company has partnered with the National Marrow Donor Program (NMDP)/Be The Match organization to conduct a Phase 2 study to advance the therapy’s development.Reflecting another positive, Nierengarten commented, “MGTA is currently advancing their anti-CD-117 amanitin-based ADC for non-genotoxic, selective stem cell ablation in IND-enabling studies and expects to enter the clinic soon and have data next year. We look forward to early data, which should also be rapidly obtained once the company enters the clinic.”It should also be noted that the company is working with AVROBIO and Beam Therapeutics, with MGTA potentially applying its technology to their gene therapy and gene editing programs. Nierengarten added, “The company is also advancing their CD45-ADC lead candidate through IND-enabling studies program for eventual use immune reset via killing disease-causing aberrant T-cells.”To sum it all up, the Wedbush analyst stated, “Overall, 2021 should have several data releases from clinical studies that will be predictive of future success, given the nature of MGTA's programs.”Everything that MGTA has going for it convinced Nierengarten to stay with the bulls. As a result, he rates MGTA an Outperform (i.e. Buy) rating, along with a $22 price target. This target conveys his confidence in MGTA’s ability to climb 202% higher in the next twelve months.Other analysts don’t beg to differ. Out of 3 total reviews published in the last three months, all 3 analysts rated the stock a Buy. Therefore, MGTA is a Strong Buy. The $17.33 average price target implies shares could appreciate by 138% in the coming year. (See Magenta stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
  • 08/13/2020

Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the second quarter ended June 30, 2020.
  • 08/06/2020

Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to
  • 08/06/2020

Here's What Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shareholder Ownership Structure Looks Like

  • A look at the shareholders of Magenta Therapeutics, Inc. (NASDAQ:MGTA) can tell us which group is most powerful...
  • 08/04/2020

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following August investor conferences:
  • 08/03/2020

Magenta Therapeutics (NASDAQ:MGTA) Downgraded to Sell at BidaskClub

  • Magenta Therapeutics (NASDAQ:MGTA) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, BidAskClub reports. Other equities analysts also recently issued research reports about the company. Wedbush reiterated a “buy” rating and issued a $22.00 price objective on shares of Magenta […]
  • 08/03/2020

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to
  • 08/03/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, July 15, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such.
  • 07/15/2020

Here is What Hedge Funds Think About Magenta Therapeutics, Inc. (MGTA)

  • How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
  • 07/08/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, NY / ACCESSWIRE / July 6, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...
  • 07/06/2020

Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session

  • Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
  • 07/06/2020

Big DraftKings Investor Bought Up an Embattled Biotech Stock

  • An Atlas Venture affiliate just paid $10 million for more shares of Magenta Therapeutics. Atlas is also the fourth-largest shareholder in sports-betting company DraftKings.
  • 07/05/2020

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $69.0 million.
  • 06/30/2020

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell
  • 06/30/2020

Why Shares of Magenta Therapeutics Are Plunging Today | The Motley Fool

  • The company announced the pricing of a public offering of common stock.
  • 06/25/2020

Magenta Therapeutics Announces Pricing of Public Offering

  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $60.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Magenta.
  • 06/25/2020

Magenta Therapeutics Announces Pricing of Public Offering

  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell
  • 06/25/2020

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA | MarketScreener

  • 06/24/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
  • 06/24/2020

Magenta Therapeutics Launches Proposed Public Offering

  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Magenta.
  • 06/24/2020

Magenta Therapeutics Launches Proposed Public Offering

  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell
  • 06/24/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Magenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • 06/22/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...
  • 06/20/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, NY / ACCESSWIRE / June 17, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...
  • 06/17/2020

Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference

  • 06/17/2020

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • 06/16/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Magenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • 06/16/2020

Biogen's NURTURE Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BIIB)

  • Biogen reports positive data from the NURTURE study. Magenta quits inherited metabolic disorder study. Clovis completes enrolment in RUBRACA study.
  • 06/16/2020

MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm

  • Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Investors who purchased Magenta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mgta.
  • 06/15/2020

Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

  • Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted ADC for conditioning of patients with sickle cell disease and beta-thalassemia receiving Beam’s base editing therapies. Beam is pursuing two differentiated base editing approaches to treat hemoglobinopathies: its hereditary persistence of fetal hemoglobin (HPFH) program to precisely and robustly elevate fetal hemoglobin, which could be used in treatments for both sickle cell disease and beta-thalassemia, as well as a novel approach to directly correct the sickle causing point mutation (Makassar).
  • 06/15/2020

Analysts Are Bullish on These Healthcare Stocks: Magenta Therapeutics (MGTA), Viela Bio (VIE) - Markets

  • There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Magenta Therapeutics
  • 06/15/2020

Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

  • Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement
  • 06/15/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • NEW YORK, NY / ACCESSWIRE / June 13, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...
  • 06/13/2020

MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm

  • NEW YORK, NY / ACCESSWIRE / June 12, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") ...
  • 06/12/2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

  • Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Magenta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • 06/11/2020

Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to...
  • 06/11/2020

Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today provided a portfolio update, highlighting progress and recent updates across its most advanced programs.
  • 06/11/2020

Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Subsequent Patient Transplant

  • Magenta Therapeutics (Nasdaq: MGTA) and the National Marrow Donor Program® (NMDP)/Be The Match®, the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia, lymphoma and other diseases, today announced a clinical collaboration agreement to evaluate the potential utility of MGTA-145, Magenta’s investigational first-line stem cell mobilization program, for mobilizing and collecting hematopoietic stem cells from donors in a single day and then using them for allogeneic transplants in patients. This life-saving procedure is currently used in approximately 28,000 patients in the U.S. and Europe each year, but approximately 62,000 additional eligible patients do not receive an allogeneic transplant due to challenges, including difficulty with the donation process.
  • 06/11/2020

Magenta Therapeutics' Shares March Higher, Can It Continue?

  • As of late, it has definitely been a great time to be an investor in Magenta Therapeutics.
  • 06/11/2020

New milestone for Hrvatski Telekom

  • The converged telecom service Magenta 1 operated by the Croatian incumbent Hrvatski Telekom (HT) is now received in more than 250,000 households.
  • 06/11/2020

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11th, 2020. The Company will also hold investor meetings and participate in a panel discussion on novel approaches for gene therapy on Monday, June 15th at the Raymond James Human Health Innovation Conference.
  • 06/08/2020

Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported the presentation of preclinical data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. Magenta also highlighted data from its Phase 1 study of first-line stem cell mobilization therapy MGTA-145. These results were presented this week at the European League Against Rheumatism (EULAR) annual meeting.
  • 06/05/2020

Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transp
  • 06/05/2020

Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical data on its stem cell mobilization therapy clinical candidate, MGTA-145, this week at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
  • 05/14/2020

Avrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma

  • Avrobio and Magenta will collaborate on a novel ADC. Adverum reports positive wet AMD data. AstraZeneca's Farxiga is approved.
  • 05/07/2020

Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results

  • Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the first quarter ended March 31, 2020.
  • 05/07/2020

AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

  • AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today re
  • 05/07/2020

AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

  • AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIO’s investigational lentiviral gene therapies.
  • 05/06/2020

Magenta Therapeutics to Host Business Update Conference Call

  • Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates. The call will also feature a discussion of current stem cell transplant practices by a transplant key opinion leader.
  • 04/30/2020

Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data from across its portfolio will be presented at the ASGCT annual meeting, to be held May 12-15, 2020.
  • 04/28/2020

Magenta Therapeutics Inc (NASDAQ:MGTA) Shares Purchased by Geode Capital Management LLC

  • Geode Capital Management LLC raised its stake in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 258,640 shares of the company’s stock after acquiring an additional 15,141 shares during the period. Geode Capital […]
  • 04/28/2020

Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promoted John Davis Jr., M.D., M.P.H., M.S. to Head of Research and Development and Chief Medical Officer.
  • 04/17/2020

Magenta Therapeutics Provides Business Update

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today provided a current update on its programs, business and operations.
  • 04/16/2020

Magenta Therapeutics Inc (NASDAQ:MGTA) Expected to Announce Earnings of -$0.61 Per Share

  • Equities analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce earnings of ($0.61) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Magenta Therapeutics’ earnings. The lowest EPS estimate is ($0.68) and the highest is ($0.57). Magenta Therapeutics reported earnings per share of ($0.44) in the same […]
  • 04/12/2020

We Think Magenta Therapeutics (NASDAQ:MGTA) Can Afford To Drive Business Growth

  • Just because a business does not make any money, does not mean that the stock will go down. For example, although...
  • 04/07/2020

The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

  • Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) (follow-on rally from Friday's news of FDA authorization
  • 03/24/2020

The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

  • Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) Arcutis Biotherapeutics...
  • 03/24/2020

The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

  • Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
  • 03/13/2020

Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights.
  • 03/03/2020

3 Monster Growth Stocks That Can Charge Forward in 2020

  • The big marquee names tend to get the most love and attention from investors and analysts alike. Monoliths like Apple, Amazon and Facebook have provided incredible returns for investors over the years. While there is room for further upside, the question for growth minded investors is how much further can these mega-caps really soar.So, have latecomers missed the boat on these ubiquitous corporations as far as sky-high returns are concerned? Possibly. But no matter, there’s always opportunity for those willing to seek it out. The big names get all the press, but some of the little guys have been making giant strides in the market, too. What’s more, the lower valuation means these companies further down the food chain have ample room for growth.With this in mind, we used TipRanks’ Stock Screener tool to find three tickers that not only grew substantially in 2019, but also boast huge upside potential in the year ahead. Let’s dig a little deeper.Evofem Biosciences Inc. (EVFM)First up, we come across a small company in the biotech space. In fact, with a market cap of just $264.5 million, Evofem qualifies as a micro-cap. If things work out for the women's sexual and reproductive health products company as some on the Street predict, it won’t be staying in small-cap territory for long.Last year, Evofem added an impressive 47% to its share price. Investors were excited about the progress of the company’s lead candidate Amphora, a non-hormonal woman-controlled vaginal gel. The product completed a Phase 3 clinical trial for the prevention of pregnancy last year, with top-line data meeting the primary endpoint. Evofem has resubmitted a marketing application to the FDA for the approval of Amphora for a contraception indication, with a PDUFA date set for May 25 (the company received a CRL for the application in 2016). Adding to the good news, Amphora is also being evaluated in clinical trials for the prevention of chlamydia and gonorrhea in women. Positive top-line results from the AMPREVENCE Phase 2b trial were announced in December.Oppenheimer’s Leland Gershell likes what he’s seeing when it comes to Evofem. The 5-star analyst recommends “investors take advantage of current levels to build a position in EVFM."Gershell further added, “Amphora's Phase 2b trial in STI prevention, which demonstrated significant reductions in chlamydia and gonorrhea infection in sexually-active women, came as a positive surprise as investors had been focused on the initial contraception opportunity. We expect eventual label expansion to STI prevention to be enabled by a single confirmatory trial, to begin in 2H20. With Amphora set to be a non-hormonal, use-on-demand contraceptive as well as the only non-barrier method to prevent sexually-transmitted infections, we have revised our projections to capture the incremental STI opportunity.”The positive data prompted Gershell to reiterate an Outperform rating on Evofem and give the price target a considerable increase - from $11 to $20, as it happens. The implications? Possible upside of a sky scraping 254%. (To watch Gershell’s track record, click here)Two fellow analysts tracked over the last three months concur. Therefore, Evofem’s additional Buy ratings coalesce into a Strong Buy consensus rating. While not quite as mercurial as Gershell’s thesis, the average price target of $14.33 indicates possible upside of an impressive 154%. (See Evofem stock analysis on TipRanks) Magenta Therapeutics Inc. (MGTA)If you’re looking for growth stocks, you could do a lot worse than Magenta Therapeutics. The small-cap’s share price increased by a massive 162% in 2019. Boosted by positive pipeline updates and encouraging data, the share price was sent soaring. 2020 has started out rather more tentatively for Magenta – the stock has pulled back by 19% since the start of the year. Some on the Street, though, believe now is the right time to pull the trigger on this promising biotech.Magenta’s focus is on the use of stem cell transplants to reset patients’ immune systems and, therefore, cure autoimmune diseases, blood cancers and genetic diseases. Currently, radiation and chemotherapy are more widely used to kill disease-causing cells, which in turn, can lead to unwanted side effects such as toxicity and infertility, a situation Magenta hopes to rectify.The company has several candidates in various stages of development. Its lead candidate is CD117-ADC, a drug designed to enable curative stem cell transplant or gene therapy by removing the genetically mutated cells in the bone marrow that cause certain genetic diseases. Preclinical data has shown promising results, and management expects to present initial clinical data for MGTA-117 in 2021.BTIG’s Amanda Murphy sees no reason for the recent sell-off and suggests investors buy on the weakness. Murphy said, “In our view, the future of the company is dependent on the success of its conditioning programs. We elected to be conservative in our market model by limiting the addressable market for these products to indications where the procedure is already well-established and considered standard of care (i.e., blood cancers); however, we see considerable upside if Magenta is able to increase adoption in indications where the procedure is not widely used despite being the only curative treatment option (i.e., autoimmune diseases and hemoglobinopaties). There is also potential for these programs to be used prior to stem cell gene therapy.”Accordingly, then, Murphy reiterated a Buy rating on Magenta along with a price target of $20. A handsome gain of 62% could be heading investors’ way should her price target materialize over the next year. (To watch Murphy’s track record, click here)Out on the Street, only two other analysts currently have a view on the promising biotech. One suggests a Buy, while the other recommends a Hold. Added together, Magenta receives a Moderate Buy consensus rating. The average price target of $19 suggests possible upside of a plentiful 54%. (See Magenta stock analysis on TipRanks) DHT Holdings (DHT)Although not quite as mercurial as Magenta’s 2019, DHT Holdings’ gains in 2019 are nothing to be sniffed at. An increase of 96% would be considered an extremely successful year in anyone’s book. So far in 2020, though, the Bermuda-based oil tanker owner-operator is sailing on choppy waters; the share price is down by 32% year-to-date.New shipping regulation, which came into effect at the start of the year, in addition to sanctions on China’s COSCO Dalian shipping unit (for transporting Iranian crude oil) sent VLCC spot shipping rates through the roof last year. Tanker rates, though, have gone down in 2020. Add to this congestion in China ports, the uncertainty amidst the coronavirus scare and an earnings miss in the last quarterly report as additional reasons for downward pressure on the stock this year.Right now, the tanker market is in the midst of a perfect storm of uncertainty and seasonality. However, Evercore’s Jonathan Chappell expects the situation to “eventually correct amid a strong fundamental backdrop.”Chappell said, “Even with rates declining meaningfully amid usual seasonal refinery demand softness and the initial panic regarding the coronavirus, DHT is still set up to generate record profitability and robust dividends in both 2020 and 2021. Unless the virus ends up being a black swan event that hurts global oil demand by one million barrels per day or more for an extended period of time, the muted orderbook should provide a buffer to crude tanker rates.”What does this mean for investors, then? It means Chappell kept his Outperform rating on DHT as is. The price target, though, comes down a notch, from $12 to $11. The new figure still implies substantial upside potential of 97%. (To watch Chappell’s track record, click here)With 2 Buys and 1 Hold, the consensus on the Street is that DHT is a Moderate Buy. Should the average price target of $8.93 be met over the coming months, investors will be taking home a 60% profit. (See DHT stock analysis on TipRanks)
  • 02/16/2020

Galaxy S20 on T-Mobile: Everything you need to know

  • The Galaxy S20 series makes the most out of T-Mobile's 5G network with support for its low-band and high-band 5G as well as future support for Sprint's mid-band signal.
  • 02/14/2020

Which unlimited plan should you buy: AT&T, Sprint, T-Mobile or Verizon?

  • All four major carriers in the U.S. offer unlimited data plans. But which is the best?
  • 01/08/2020

Did Hedge Funds Drop The Ball On Magenta Therapeutics, Inc. (MGTA) ?

  • The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
  • 12/20/2019

Improving Stem Cell Transplant Success Rates

  • When it comes to investing in biotech, we know there's a ton of money to be made, but also a ton of money to be lost. For every Foundation Medicine story there's a Bind Therapeutics story to accompany it. For exposure to the healthcare sector, we're happy to hold solid dividend growth investing stocks like Johnson and Johnson or Medtronic which have not only paid but increased their dividends for 56 and 46 years respectively at a rate that has more than exceeded inflation. When your job involves writing insightful articles and offering them to your lovely readers for free, you need some cash coming
  • 05/28/2018

Quick Update - Under 2 Weeks Remaining - ADC Conference -

  • ADC Summit
  • 04/03/2018
Unlock
DNTH Ratings Summary
DNTH Quant Ranking